Waters CORP /DE/ Form 4 insider transactions

Waters Corporation details its strategic transformation and the significant value creation expected from its proposed acquisition of BD's Bioscience and Diagnostics business, targeting enhanced growth and market leadership.

Waters Corporation presented at the J.P. Morgan Healthcare Conference, detailing its proposed acquisition of Augusta SpinCo Corporation from Becton, Dickinson and Company and outlining its strategic and financial outlook.

Augusta SpinCo Corporation, a BD subsidiary, has entered into a $4 billion unsecured term loan credit agreement to finance its spin-off from BD and subsequent merger with Waters Corporation.

Waters Corp Director Mark Vergnano acquired 307 shares of common stock and 828 stock options, with vesting scheduled for January 2, 2027.

Waters Corp Director Christopher A. Kuebler received 307 restricted common shares and 828 stock options, vesting in 2027.

Waters Corp Director Pearl S. Huang reported the acquisition of restricted common stock and stock options under a pre-arranged plan.

Waters Corp Director Richard H. Fearon was granted 307 shares of restricted common stock and options to purchase 828 shares of common stock.

Waters Corp Director Daniel J. Brennan was granted 307 restricted shares of common stock and options to purchase 828 shares.

Waters Corp director Linda Baddour acquired 307 shares of common stock and 828 stock options, effective January 2, 2026, as part of her compensation.

Waters Corp. Director Flemming Ornskov reported the acquisition of 307 shares of common stock and 828 stock options, signaling increased insider ownership.

Waters Corp Director Wei Jiang reported acquiring additional common stock units, restricted shares, and stock options, increasing beneficial ownership.

Waters Corp Director Heather Knight reported acquiring common stock units, restricted stock, and stock options as part of her compensation.

Waters Corporation is set to acquire Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business in a Reverse Morris Trust transaction valued at approximately $17.5 billion, aiming for significant growth and synergies.

Waters Corporation provides an update on its proposed business combination with BD's Biosciences and Diagnostic Solutions businesses, highlighting integration progress, new product achievements, and regulatory filings.

CEO Udit Batra detailed integration progress, product launches, and stronger chemistry growth as Waters advances the proposed combination with BD’s Augusta SpinCo.

Waters Corporation provides an update on the integration planning for its proposed business combination with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses.

Waters Corporation addresses employee concerns regarding the upcoming business combination with BD's Biosciences and Diagnostic Solutions businesses, outlining plans for leadership, compensation, benefits, and facilities.

Waters Corp. Director Christopher Kuebler exercised stock options and increased his direct common stock holdings by a net of 2,443 shares.

Waters Corporation reports strong third-quarter 2025 financial results, exceeding guidance, and provides positive updates on its pending combination with BD's Biosciences & Diagnostic Solutions business.

Waters Corporation provides an update on its proposed business combination with BD's Biosciences & Diagnostic Solutions business, confirming leadership and integration progress.

Waters Corp. Director Heather Knight acquired 77.88 common stock units as part of her director compensation, increasing her beneficial ownership to 759.28 units.

Waters Corp. Director Wei Jiang acquired 72.91 common stock units as part of a deferred compensation plan, increasing total beneficial ownership to 2,551.48 units.

Waters Corporation provides an update on the integration planning for its proposed business combination with BD's Biosciences and Diagnostic Solutions business, expected to close by Q1 2026.

Waters Corporation's CEO, Udit Batra, outlined the compelling strategic fit and significant synergy opportunities driving the proposed business combination with BD's Augusta SpinCo.

Waters Corporation's CEO, Udit Batra, outlined the strategic advantages of combining with BD's SpinCo, emphasizing enhanced clinical mass spectrometry and expanded specialty diagnostics.

Waters Corporation's CEO Udit Batra outlined the strategic rationale and significant synergy potential of the proposed acquisition of BD's biosciences and diagnostic solution business.

Waters Corporation reported strong second-quarter 2025 financial results, exceeding guidance and raising full-year outlook, while detailing strategic benefits and integration plans for its pending acquisition of BD's Biosciences and Diagnostic Solutions business.

Waters Corporation announced strong second-quarter 2025 financial results and provided an update on its proposed business combination with Augusta SpinCo Corporation, a subsidiary of Becton, Dickinson and Company.

Waters Corporation reported strong second-quarter 2025 financial results, exceeding sales guidance and raising full-year sales and non-GAAP EPS outlook, driven by robust instrument replacement trends and strategic growth initiatives.

Waters Corporation's CEO, Udit Batra, voiced strong confidence in the proposed business combination with Augusta SpinCo Corporation, acknowledging the transaction's larger-than-anticipated scale and the need for patience.